Tom Lillie is CMO at Grey Wolf Therapeutics, a company focused on using ERAP inhibition to overcome resistance in immuno-oncology. Dr Lillie completed his undergraduate training at Brasenose College, University of Oxford, where he was awarded a first-class degree in pharmacology, cell biology and immunology, before earning his doctorate in cell biology from the Department of Physiology at the University College of London. He then completed his medical education at the University College London Medical School, receiving honours distinction in clinical pharmacology and surgery. He is a member of the Royal College of Surgeons of England and the Faculty of Pharmaceutical Medicine of the Royal College of Physicians.
Tom has led global, regional and affiliate medical teams, encompassing both early and late-stage clinical development and medical affairs functions. He has extensive experience in clinical research in phase 1 – phase 4, and in supporting regulatory, safety and reimbursement interactions. During his clinical and industry career he has specialised in oncology & haematology, but has also worked in cardiovascular, metabolic, vaccine, anti-infective and neurologic disease areas.